FDA's 2026 AI Device Scrutiny: Lifecycle Governance and Real-World Performance

This episode explores the FDA's expected regulatory landscape for AI-enabled medical devices in 2026. We discuss the critical shift from pre-market assessment to a total product lifecycle approach, focusing on the non-negotiable requirements for real-world performance monitoring and Predetermined Change Control Plans (PCCPs). Learn what will separate scalable, approvable medtech platforms from demo-grade algorithms that cannot withstand long-term regulatory scrutiny. - How will the FDA's definition of 'safe and effective' for AI devices change by 2026? - What is a Predetermined Change Control Plan (PCCP) and why will it be mandatory? - Why is real-world performance monitoring becoming more critical than initial pilot data? - What is 'algorithmic drift' and how must manufacturers plan to manage it? - How does clinical workflow integration impact the regulatory viability of an AI device? - What separates a sustainable medtech platform from a simple AI algorithm? - How can you build a lifecycle governance strategy that meets future FDA expectations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From developing a regulatory strategy and compiling your technical dossier to acting as your local representative in over 30 markets, we cover the entire product lifecycle. Our technology-driven approach ensures efficiency and accuracy, helping you navigate complex requirements for market approval and post-market surveillance. To access new markets faster and ensure ongoing compliance, contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.